Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Intermediate Term Corporate Bond ETF (VCIT) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance

Vanguard Intermediate Term Corporate Bond ETFTrade
Health Care Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

Vanguard Intermediate Term Corporate Bond ETF vs Health Care Select Sector SPDR Fund — how do they compare? Vanguard Intermediate Term Corporate Bond ETF trades at $81.54, while Health Care Select Sector SPDR Fund trades at $160.19. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.

VCITXLV
Sector
Fixed Income
52-Week High
$84.82$164.48
52-Week Low
$81.45$129.01

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Intermediate Term Corporate Bond ETF

VCIT trades at $81.71, down 0.28% on the day, with a bearish technical signal driven by moving averages. The fund provides exposure to intermediate-term corporate bonds, offering a competitive yield and low expense ratio. Recent news highlights its role in fixed-income portfolios, comparing favorably on cost and income potential against peers like iShares alternatives.

Outlook remains cautious near-term due to technical weakness, but the fund's low-cost structure and steady dividends appeal for income-focused investors. Risks include interest rate sensitivity and corporate credit conditions, requiring monitoring of economic indicators for sustained performance.

Health Care Select Sector SPDR Fund

XLV trades at $159.25, down 1.14% with neutral technical signals overall. The healthcare ETF shows mixed momentum with bullish moving averages but neutral oscillators. Recent news highlights XLV's defensive characteristics amid market volatility, with State Street upgrading healthcare to positive for Q3 2026. The fund's diversified approach offers stability compared to more volatile biotech-focused alternatives.

XLV presents a defensive opportunity with lower costs and steady performance, though upside may be limited in the current cycle. Key risks include patent cliff concerns and sector rotation away from defensive plays if market sentiment improves. The ETF's broad healthcare exposure provides cushion against individual stock volatility while benefiting from pipeline innovations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Vanguard Intermediate Term Corporate Bond ETF

VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.

Read more on VCIT

About Health Care Select Sector SPDR Fund

In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.

Read more on XLV